Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.16 +60.30 (+0.75%) Bitcoin USD
64,452.34 +976.59 (+1.54%) CMC Crypto 200
1,344.84 -51.69 (-3.70%)
Kronos Bio, Inc. (KRON)
| Previous close | 0.9800 |
| Open | 0.9790 |
| Bid | 0.9745 x 200 |
| Ask | 1.0300 x 200 |
| Day's range | 0.9600 - 1.0100 |
| 52-week range | 0.7310 - 2.2900 |
| Volume | |
| Avg. volume | 375,182 |
| Market cap | 59.512M |
| Beta (5Y monthly) | 1.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9500 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.25 |
GlobeNewswireKronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 (NCT04718675), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 –
ZacksKronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
Kronos Bio (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence in the first half of 2025 $175.0 million in cash, cash equivalents and investments as of December 31, 2023, providing expected cash runway into the second half of 2026 SAN MATEO, C
